A Phase III Extension Trial With a 1-Arm Crossover From Leuprolide to Degarelix: Comparison of Gonadotropin-Releasing Hormone Agonist and Antagonist Effect on Prostate Cancer

Article ID	Journal	Published Year	Pages	File Type
3865351	The Journal of Urology	2011	9 Pages	PDF

Abstract

Data support the statistically significant prostate specific antigen progression-free survival benefit for degarelix over leuprolide seen during year 1 and the use of degarelix as first line androgen deprivation therapy as an alternative to a gonadotropin-releasing hormone agonist.

Keywords

ADT GnRH PSA PCA PFs ALP Alkaline phosphatase Prostate specific antigen progression-free survival ADT, Androgen deprivation therapy Prostate cancer adverse event Leuprolide Prostatic neoplasms Gonadotropin-releasing hormone follicle-stimulating hormone luteinizing hormone FSH Prostate

Related Topics

Health Sciences Medicine and Dentistry Nephrology

Preview

A Phase III Extension Trial With a 1-Arm Crossover From Leuprolide to Degarelix: Comparison of Gonadotropin-Releasing Hormone Agonist and Antagonist Effect on Prostate Cancer

Authors

E. David Crawford, Bertrand Tombal, Kurt Miller, Laurent Boccon-Gibod, Fritz Schröder, Neal Shore, Judd W. Moul, Jens-Kristian Jensen, Tine Kold Olesen, Bo-Eric Persson,